Clinical application areas and regimens Recognan (citicoline) treatment in neurology

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Many studies have demonstrated Recognan (citicoline) per oral (p/o) administration clinical effectiveness in the treatment of cerebrovascular diseases (CVD): in the recovery period of acute cerebrovascular accident (ACVA), in the recovery period of traumatic brain injury (TBI), in the prevention and complex therapy of cognitive impairment (CI) of various types. genesis, including against the background of type 2 diabetes mellitus (DM-2), in the complex treatment of asthenia and anxiety conditions. The article provides treatment regimens for Recognan: for acute vascular conditions, the dosage is 1000-2000 mg/day, and for chronic conditions, the dosage is 500 mg/day. The duration of Recognan treatment is determined by the doctor and ranges from 3 to 18 months, depending on the severity of the neurological symptoms.

Full Text

Restricted Access

About the authors

Olga A. Shavlovskaya

International University of Restorative Medicine

Author for correspondence.
Email: shavlovskaya@1msmu.ru
ORCID iD: 0000-0003-3726-0730

Dr. Sci. (Med.), Professor, Department of Restorative Medicine and Medical Rehabilitation

Russian Federation, Moscow

References

  1. Secades J.J. Citicoline: pharmacological and clinical review, 2010 update. Rev Neurol. 2011;52(suppl 2):1–62. PMID: 21432836
  2. Secades J.J. Citicoline: pharmacological and clinical review, 2016 update. Rev Neurol. 2016;63(S03):S1–S73. PMID: 28417449
  3. Secades J.J., Gareri P. Citicoline: pharmacological and clinical review, 2022 update. Rev Neurol. 2022;75(Supl. 5):S1–89. https://doi.org/10.33588/rn.75S05.2022311
  4. Шавловская О.А., Бокова И.А. Эффективность и безопасность Рекогнана (цитиколин) при коррекции когнитивных нарушений различной этиологии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(11):22–28. [Shavlovskaya O.A., Bokova I.A. Recognan (citicoline) efficacy and safety in cognitive impairment correction of various nosological forms. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(11):22–28. (In Russ.)]. https://doi.org/10.17116/jnevro202312311122
  5. Шавловская О.А. Оценка эффективности терапии цитиколином в остром и восстановительном периодах инсульта. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;116(6):93–97. [Shavlovskaya O.A. The assessment of the efficacy of citicoline in the early and recovery stages of stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(6):93–97. (In Russ.)]. https://doi.org/10.17116/jnevro20161166193-97
  6. Ткачева О.Н., Яхно Н.Н., Незнанов Н.Г., и др. Клинические рекомендации «Когнитивные расстройства у лиц пожилого и старческого возраста». Журнал неврологии и психиатрии им. С.С. Корсакова. 2025;125(3 3):7–149. [Tkacheva O.N., Yahno N.N., Neznanov N.G., et al. Clinical guidelines «Cognitive disorders in the elderly and senile persons». S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(3 3):7–149. (In Russ.)]. https://doi.org/10.17116/jnevro2025125337
  7. Путилина М.В., Теплова Н.В. Синергизм лекарственных препаратов как основа рациональной нейропротекции. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(5):17–22. [Putilina M.V., Teplova N.V. Drug synergism as a basis for rational neuroprotection. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(5):17–22. (In Russ.)]. https://doi.org/10.17116/jnevro202212205117
  8. Белова Л.А., Машин В.В., Дудиков Е.М., и др. Многоцентровая наблюдательная программа по оценке эффективности комплексной терапии препаратами кортексин и рекогнан (цитиколин) когнитивных нарушений у пациентов с хронической цереброваскулярной патологией. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(2):35–38. [Belova L.A., Mashin V.V., Dudikov E.M., et al. A multicenter observation study of the efficacy of cortexin and recognan (citicoline) in the treatment of cognitive impairments in chronic cerebrovascular pathology. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2):35–38. (In Russ.)]. https://doi.org/10.17116/jnevro201911902135
  9. Шавловская О.А. Эффективность Рекогнана (цитиколин) у пациентов с цереброваскулярными заболеваниями и сахарным диабетом 2 типа. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;124(9):23–27. [Shavlovskaya O.A. Recognan (citicoline) prescribing in cerebrovascular diseases and type 2 diabetes mellitus patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(9):23–27. (In Russ.)]. https://doi.org/10.17116/jnevro20241240911
  10. Bonvicini M., Travaglini S., Lelli D., et al. Is citicoline effective in preventing and slowing down dementia? A systematic review and a meta-analysis. Nutrients. 2023;15(2):386. https://doi.org/10.3390/nu15020386
  11. Castagna A., Fabbo A., Manzo C., et al. A retrospective study on the benefits of combined citicoline, memantine, and acetylcholinesterase inhibitor treatments in older patients affected with alzheimer’s disease. J Alzheimers Dis. 2021;79(4):1509–1515. https://doi.org/10.3233/JAD-20121
  12. Castagna A., Cotroneo A.M., Gareri P., Ruotolo G. The CITIRIVAD study: CITIcoline plus RIVAstigmine in elderly patients affected with dementia study. Clin Drug Investig. 2016;36(12):1059–1065. https://doi.org/10.1007/s40261-016-0454-3
  13. Gareri P., Castagna A., Cotroneo A.M., Putignano D. The citicholinage study: citicoline plus cholinesterase inhibitors in aged patients affected with Alzheimer’s disease study. J Alzheimers Dis. 2017;56(2):557–565. https://doi.org/10.3233/JAD-160808
  14. Alvarez-Sabin J., Ortega G., Jacas C., et al. Long-term treatment with citicoline may improve poststroke vascular cognitive impairment. Cerebrovasc Dis. 2013;35(2):146–154. https://doi.org/10.1159/000346602
  15. Cotroneo A.M., Castagna A., Putignano S., et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin Interv Aging. 2013;8:131–137. https://doi.org/10.2147/CIA.S38420
  16. Li Z., Wang P., Yu Z., et al. Effect of citicoline adjuvant therapy on mild cognitive impairment in Parkinson’s disease. Int J Clin Exp Med. 2016;9:4593–4598.
  17. Шавловская О.А. Эффективность применения Рекогнана для коррекции неврологических нарушений после перенесенной черепно-мозговой травмы. Журнал неврологии и психиатрии им. С.С. Корсакова. 2025;125(7):41–45. [Shavlovskaya O.A. Efficacy of Recognan in the therapy of neurological disorders after traumatic brain injury. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(7):41–45. (In Russ.)]. https://doi.org/10.17116/jnevro20251250711
  18. Шавловская О.А., Бокова И.А. Коррекция астенических состояний препаратом Рекогнан. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;124(3):57–62. [Shavlovskaya O.A., Bokova I.A. Asthenic disorders correction with Recognan. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(3):57–62. (In Russ.)]. https://doi.org/10.17116/jnevro202412403157
  19. Шавловская О.А. Астения: диагностический алгоритм, терапевтический подход. Фарматека. 2024;31(6):239–243. [Shavlovskaya O.A. Asthenia: diagnostic algorithm, therapeutic approach. Farmateka. 2024;31(6): 239–243. (In Russ)]. https://doi.org/10.18565/ pharmateca.2024.6. 239-243
  20. Шавловская О.А. Рекогнан (цитиколин) в коррекции астенических и тревожно-депрессивных нарушений. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;124(6):43–47. [Shavlovskaya O.A. Recognan (citicoline) in the correction of asthenic and anxiety-depressive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(6):43–47. (In Russ.)]. https://doi.org/10.17116/jnevro202412406143

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1

Download (229KB)
Indexing metadata

Copyright (c) 2025 Bionika Media